[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE3908822A1 - New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume - Google Patents

New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume

Info

Publication number
DE3908822A1
DE3908822A1 DE19893908822 DE3908822A DE3908822A1 DE 3908822 A1 DE3908822 A1 DE 3908822A1 DE 19893908822 DE19893908822 DE 19893908822 DE 3908822 A DE3908822 A DE 3908822A DE 3908822 A1 DE3908822 A1 DE 3908822A1
Authority
DE
Germany
Prior art keywords
active ingredient
capsule
terms
drug
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19893908822
Other languages
German (de)
Inventor
Erfinder Wird Nachtraeglich Benannt Der
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19893908822 priority Critical patent/DE3908822A1/en
Publication of DE3908822A1 publication Critical patent/DE3908822A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Published without abstract.

Description

Die Erfindung betrifft ein Verfahren und eine Vorrichtung, mit dessen Hilfe Arzneistoffe, vorzugsweise in pastöser oder flüssiger Form, evtl. unter Zuhilfenahme von penetrations­ vermittlern, wie beispielsweise DMSO, mengen- und zeitmäßig gezielt in das Untergewebe der Haut eingebracht werden kann.The invention relates to a method and a device, with the help of drugs, preferably in pasty or liquid form, possibly with the help of penetrations intermediaries, such as DMSO, in terms of quantity and timing can be specifically introduced into the lower tissue of the skin can.

Auch ist eine implantierfähige Form einer Kapsel denkbar, oder die elektronisch steuerbare Wirkstoffkapsel kann als Depotsystem z. B. im Rachenraum "verankert" werden, um dort, in abstimmbaren Intervallen einen geeigneten Wirkstoff abzugeben.An implantable form of a capsule is also conceivable or the electronically controllable active ingredient capsule as a deposit system z. B. "anchored" in the pharynx, to find a suitable one there at adjustable intervals Deliver active ingredient.

Besonders vorteilhaft ist jedoch diese Vorrichtung, wenn sie als steuerbare Wirkstoffkapsel, im Bereich der trans­ dermalen Systeme (subkutan wirkende Pflaster mit Wirk­ stoffen), eingesetzt wird. However, this device is particularly advantageous if it as a controllable active ingredient capsule, in the field of trans dermal systems (subcutaneously acting plasters with active substances) is used.  

Der Vorteil dieser neuen Präparateform besteht auch darin, daß, besonders bei älteren, wohlmöglich vergeßlichen Patienten, die Wirkstoffabgabe vom Arzt oder von der programmierbaren (oder fest programmierten) Wirkstoffkap­ sel her festgelegt werden kann. Auch kann eine Ansteuer­ einheit (Uhrenbaustein) die Abgabe von Wirkstoff z. B. während einer Ruhephase (Nacht) reduzieren oder gänzlich abstellen.The advantage of this new form of preparation is also that that, especially with older ones, is probably forgetful Patients receiving drug delivery from the doctor or from the programmable (or permanently programmed) active ingredient cap sel her can be determined here. Can also be a control unit (clock module) the delivery of active ingredient z. B. reduce during a rest period (night) or completely Off.

Das war mit den bisherigen transdermalen Systemen nicht möglich.That was not the case with the previous transdermal systems possible.

Die Erfindung betrifft eine den Wirkstoff enthaltende De­ potkammer, die wiederum mit einer elektrochemischen Zelle, (wie sie z. Bs. von der Firma Simatec AG, CH 3360 Herzogen­ buchsee hergestellt wird) verbunden ist, die beim Kurz­ schließen der beiden Pole Wasserstoffgas (oder auch Sauer­ stoff) bildet. Damit wird nun, vorzugsweise durch eine geeignete Folie getrennt, Druck auf die Wirkstoffblase (hier als Depotkammer bezeichnet) ausgeübt. Über eine kommunizierende Kanäle oder eine kapillarisch/transparente Folie, die mit der üblichen Heftpflastertechnik auf der Haut, an geeigneter Stelle angebracht, wird nun der Wirk­ stoff zeitlich- und mengenmäßig gezielt abgegeben.The invention relates to a De containing the active ingredient pot chamber, which in turn has an electrochemical cell, (as e.g. from Simatec AG, CH 3360 Herzogen buchsee) is connected, which is short close the two poles of hydrogen gas (or acid fabric) forms. So now, preferably by a suitable film separated, pressure on the active ingredient bladder (here referred to as the depot chamber). Over a communicating channels or a capillary / transparent Foil made with the usual adhesive plaster technique on the Skin, placed in a suitable place, now becomes active Targeted release of material in terms of time and quantity.

Die Gasproduktion ist praktisch äquivalent zum Strom, d. h., die Gasmenge pro Zeiteinheit kann über einen Außen­ widerstand fixer oder verstellbarer Art bestimmt werden. Die Gaszellen arbeiten ohne leglichen Fremdstrom. Die Abmessungen einer Gasentwicklungszelle betragen etwa 7.8×3.5 mm. Die Kapazität liegt, je nach Typ, bei ca. 25-150 ml H2-Gas.Gas production is practically equivalent to electricity, ie the amount of gas per unit of time can be determined via an external resistance of a fixed or adjustable type. The gas cells work without legal external electricity. The dimensions of a gas development cell are approximately 7.8 × 3.5 mm. Depending on the type, the capacity is approx. 25-150 ml H 2 gas.

Die Erfindung sieht nun eine feste Verbindung mit einem, per SMD-Technik gebauten Mikrochip vor. Wobei die kom­ plette Einheit: (für den Antrieb) die Gasentwicklungs­ zelle, eine Depotkammer (die den Wirkstoff enthält), das Übertragungselement (eine durchlässige Folie oder ein Kanülensystem), sowie der ob. erwähnte Steuerchip, die Wirkstoffkapsel bilden.The invention now sees a fixed connection with a Microchip built using SMD technology. Whereby the com Plette unit: (for the drive) the gas development cell, a depot chamber (containing the active ingredient) that Transmission element (a permeable film or a Cannula system), as well as the above-mentioned control chip, the Form active ingredient capsule.

Es ist auch eine Plazierung dieser Wirkstoffkapsel im Rectum oder im vaginalen Bereich denkbar.It is also a placement of this drug capsule in the rectum or conceivable in the vaginal area.

Es ist auch eine Ausführung denkbar, bei der der Wirkstoff, bzw. die Gaserzeugung als Treibmedium, über einen (Glu­ cose-) Sensor gesteuert wird, um z. Bs. bei Diabetes­ patienten die Insulinabgabe zu regeln. Diese neuen transdermale Systeme könnten ein zusätzliches akus­ tisches (Pfeifton) Signal abgeben, damit der Patient den Zeitpunkt der Wirkstoffabgabe kontrollieren kann. Als Funktionsprüfung wie auch zur Eigenüberwachung seines Befindens (vorher/nachher).An embodiment is also conceivable in which the active ingredient, or gas generation as a propellant, via a (Glu cose-) sensor is controlled to z. For diabetes regulate insulin delivery. These new ones transdermal systems could be an additional acus table (whistle) signal so that the patient the Can control the time of drug delivery. As Functional test as well as self-monitoring of his Condition (before / after).

Claims (5)

1. Verfahren zur gezielten Abgabe von Arzneistoffen, dadurch gekennzeichnet, daß eine als Wirkstoffkapsel bezeichnete Vorrichtung benutzt wird, die aus einer (Arzneimittel-) Depotkammer besteht, die mit mit einer Gasentwicklungszelle und einem IC (z. B. Uhrenbaustein) gekoppelt ist, um über ein zeitlich und damit mengenmäßig gesteuertes Gasvolumen, eine definierte Wirkstoffmenge herauszutreiben und dem Patienten damit zuzuführen.1. A method for the targeted delivery of drugs, characterized in that a device called an active ingredient capsule is used, which consists of a (drug) depot chamber, which is coupled to a gas development cell and an IC (z. B. clock module) to Using a gas volume controlled in terms of time and quantity, to expel a defined amount of active ingredient and thus deliver it to the patient. 2. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, daß die Wirkstoffkapsel als transdermales System ausgebildet ist (Pflaster mit integrierter Wirkstoff­ kapsel).2. The method according to claim 1, characterized in that that the drug capsule as a transdermal system trained (plasters with integrated active ingredient capsule). 3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß eine Wirkstoffkapsel benutzt wird, die dank einer glatten Formgebung geeignet ist, abgeschluckt werden zu können.3. The method according to claim 1, characterized in that an active ingredient capsule is used, which thanks to a smooth shape is suitable to be swallowed can. 4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die steuerbare Wirkstoffkapsel fest in Körperöffnungen verankert werden kann. 4. The method according to claim 1, characterized in that the controllable active ingredient capsule firmly in body openings can be anchored.   5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Wirkstoffkapsel implantiert werden kann; wobei die eingegebenen Daten zur Medikamentenfrei­ gabe, nach Überwindung eines speziellen Codes, berührungslos geändert werden können.5. The method according to claim 1, characterized in that the drug capsule can be implanted; where the data entered is drug-free after overcoming a special code, can be changed without contact.
DE19893908822 1989-03-18 1989-03-18 New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume Ceased DE3908822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19893908822 DE3908822A1 (en) 1989-03-18 1989-03-18 New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19893908822 DE3908822A1 (en) 1989-03-18 1989-03-18 New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume

Publications (1)

Publication Number Publication Date
DE3908822A1 true DE3908822A1 (en) 1990-09-20

Family

ID=6376604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19893908822 Ceased DE3908822A1 (en) 1989-03-18 1989-03-18 New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume

Country Status (1)

Country Link
DE (1) DE3908822A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US7070592B2 (en) 1999-12-10 2006-07-04 Massachusetts Institute Of Technology Medical device with array of electrode-containing reservoirs
US7985386B2 (en) 2000-03-02 2011-07-26 Microchips, Inc. Implantable medical device for diagnostic sensing

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US7892221B2 (en) 1996-07-02 2011-02-22 Massachusetts Institute Of Technology Method of controlled drug delivery from implant device
US7901397B2 (en) 1996-07-02 2011-03-08 Massachusetts Institute Of Technology Method for operating microchip reservoir device
US7918842B2 (en) 1996-07-02 2011-04-05 Massachusetts Institute Of Technology Medical device with controlled reservoir opening
US7070592B2 (en) 1999-12-10 2006-07-04 Massachusetts Institute Of Technology Medical device with array of electrode-containing reservoirs
US7985386B2 (en) 2000-03-02 2011-07-26 Microchips, Inc. Implantable medical device for diagnostic sensing

Similar Documents

Publication Publication Date Title
DE69431066T2 (en) INTRADERMAL DRUG DELIVERY DEVICE
DE69026109T2 (en) IMPLANTABLE DEVICE FOR ADMINISTRATING MEDICINAL OR OTHER LIQUID SOLUTIONS
DE69522821T2 (en) LIQUID DELIVERY DEVICE CONTROLLED BY ANALYTIC AND MONITORING OF THE ANALYTIC
DE69720057T2 (en) DEVICE AND METHOD FOR INCREASING THE TRANSDERMAL ACTIVE SUBSTANCE FLOW
EP3280484B1 (en) Micro-needle system for application of liquid formulations
US5997501A (en) Intradermal drug delivery device
DE69730971T2 (en) DEVICE FOR THE TRANSDERMALIZATION OF MEDICAMENTS OR THE ACCEPTANCE OF BODY FLUIDS
DE69534225T2 (en) DEVICE FOR THE ADMINISTRATION OF MEDICAMENTS WITH A MICROPROCESSOR AND A SIGNATURE MONITOR
DE3887145T2 (en) Medical test device.
US7544185B2 (en) Needle device comprising a plurality of needles
KR930701612A (en) In vivo delivery of activators by cocultured cell transplants
DE10041845A1 (en) Iontophoretic medicament delivery system comprises a control unit and a plaster which is applicable to the skin of a patient, and has at least two reservoirs of a medicament ionizable by the control unit
DE2513467B2 (en) Device for infusing liquids into the human or animal body
DE3121888A1 (en) PORTABLE DEVICE FOR SUBCUTANEOUS INJECTION OF A LIQUID MEDICINE
EP0230747A3 (en) Implantable infusion port
JP2008154849A (en) Injector
DE19681392B4 (en) Electrotransport device with reusable control device and preparatory method
EP2543125A2 (en) Activatable drug dispensing system
DE3908822A1 (en) New active substance microcapsule able to dispense medicinal agents in a controlled manner in terms of time and volume
DE102006017557A1 (en) Blood sugar measuring device, has ring strip for fixing device in limb such as arm or leg of user, and automatic measuring device designed in form of automatic needle that pierces from device into skin of user
WO1995004549A1 (en) Creating new capillary blood pools for practising bidirectional medicine
JP2005087521A (en) Liquid medicine injector
DE3319670A1 (en) AGENTS FOR THE ACCELERATED TRANSDERMAL APPLICATION OF ACTIVE SUBSTANCES AND NUTRIENTS
DE102016120926A1 (en) Injection device for injecting metered quantities of a liquid therapeutic agent
CN111282093B (en) Multifunctional insulin pen

Legal Events

Date Code Title Description
8131 Rejection